In experiments using the A431 human squamous cell carcinoma xenografted model which over-expresses EGFR, HER2 and HER3, the anti-tumor effects were seen with an average tumor growth delay of 21 days at doses as low as 1.2 mg/kg [70]. This evidence concerns the gene ERBB2 and neoplasm.